Molecular Pathology Laboratory Network

F IGH

immunoglobulin heavy chain, 14q32 rearrangement

Non-Hodgkin lymphoma, Myeloma

Fluorescence in situ Hybridization (FISH)

88367 x2 - Morphometric analysis, in situ hybridization, automated
88368 x2 - Morphometric analysis, in situ hybridization, manual

3 days

• 2.0 mL (min. 1.0 mL) peripheral blood in sodium heparin preferred, EDTA accepted
• 1.0 mL (min. 0.5 mL) bone marrow in sodium heparin preferred, EDTA accepted
• 5 mm^3 fresh tissue in MPLN RPMI media
• 3.0 mL (min. 2.0 mL) FNA in MPLN RPMI media
• 10% neutral buffered formalin fixed paraffin embedded tissue

• Peripheral blood and bone marrow stable at 18-25°C for 72 hours
• Fresh tissue or FNA stable at 2-8°C for 72 hours

• Whole blood and bone marrow, ship ambient
• Fresh tissue, FNA or paraffin embedded tissue, ship in a Styrofoam container with an ice pack (Do not allow ice pack to directly contact sample)

Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells; Improper fixative

See report

Rearrangements involving the IGH gene have been identified in about 50% of non-Hodgkin B-cell lymphomas (NHLs) and correlated to clinically relevant subgroups. A t(14;18)(q32;q21) is found in 88.1% of follicular lymphomas and a t(11;14)(q13;q32) is in 85.7% mantle cell lymphomas. IGH rearrangements are identified in 52.5% of diffuse large B-cell lymphomas. Rearrangements of the IgH gene occur in 34.7% of plasma cell myeloma cases and is among the most frequent chromosomal change. FISH can detect this rearrangement in either interphase or metaphase cells.